Comparative Pharmacology
Head-to-head clinical analysis: ANTIZOL versus PROVAYBLUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTIZOL versus PROVAYBLUE.
ANTIZOL vs PROVAYBLUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antizol (fomepizole) is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the oxidation of ethanol to acetaldehyde. It also inhibits the metabolism of ethylene glycol and methanol to their toxic metabolites.
Methylthioninium chloride (methylene blue) acts by reducing methemoglobin to hemoglobin via the enzyme NADPH methemoglobin reductase, thereby restoring oxygen-carrying capacity of the blood.
Initial: 15 mg/kg IV over 10 minutes, then 3 mg/kg IV every 4 hours for 2 doses, then 3 mg/kg IV every 6 hours for 4 doses.
1-2 mg/kg intravenously over 5 minutes, may repeat once if needed. Maximum single dose: 300 mg.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours in adults. Clinical context: Dose adjustment recommended in severe renal impairment (CrCl <30 mL/min) due to prolonged half-life.
Terminal elimination half-life is approximately 10-15 hours. In patients with renal impairment, half-life may be prolonged; no dose adjustment recommended for mild-to-moderate impairment, but use caution in severe impairment.
Renal: 80-95% as parent drug and metabolites. Fecal: <5%. Biliary excretion is negligible.
Primarily renal excretion as unchanged drug. Approximately 45-60% of a dose is excreted unchanged in urine. Minor fecal elimination accounts for less than 10%.
Category C
Category C
Antidote
Antidote